Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene reports business update and Q3 2023 financial position

Q3 2023 financial position

Published 7 November 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)

Transgene and BioInvent – first patient treated in Part B of Phase I trial

Published 10 October 2023
Categorized as 2023, BT-001, categorie-orpheline, dates, dates, Press release

Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024

2023 half year results and business update

Published 20 September 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene Announces Upcoming Investor Meetings

Transgene Announces Upcoming Investor Meetings

Published 14 September 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene receives $15.3 Million from the Sale of Securities Held for Sale

Transgene receives $15.3 million from the sale of securities held for sale

Published 17 July 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene and NEC present New Data on TG4050 at ASCO 2023

Published 6 June 2023
Categorized as 2023, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023

Transgene immunological data demonstrating that TG4001 can induce T-cell responses

Published 5 June 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release, TG4001, TG4001

Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting

Published 26 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Invir.IO, Myvac, Press release, TG4001, TG4050

Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors

Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001

Published 25 May 2023
Categorized as 2023, BT-001, categorie-orpheline, dates, dates, Invir.IO, Press release

Transgene provides business update and Q1 2023 financial position

business update and Q1 2023 financial position 15

Published 10 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Posts pagination

Newer posts Page 1 … Page 9 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu